Immunomedics Company Profile (NASDAQ:IMMU)

About Immunomedics

Immunomedics logoImmunomedics, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company's technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. Its product candidates include 90Y-clivatuzumab tetraxetan. Its radiolabeled antibody is in a Phase III registration trial in patients with advanced pancreatic cancer. Its portfolio of investigational products also includes antibody-drug conjugates (ADCs). Its ADCs consist of sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130), which are in Phase II trials for a number of solid tumors and metastatic colorectal cancer (mCRC), respectively. It has other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in clinical and pre-clinical development-stages.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: IMMU
  • CUSIP: 45290710
Key Metrics:
  • Previous Close: $3.27
  • 50 Day Moving Average: $2.93
  • 200 Day Moving Average: $3.00
  • 52-Week Range: $95,866,000.00 - $1.50
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -8.61
  • P/E Growth: 0.00
  • Market Cap: $313.48M
  • Outstanding Shares: 95,866,000
  • Beta: 1.47
Profitability:
  • Net Margins: -1,826.07%
  • Return on Assets: -79.15%
Debt:
  • Debt-to-Equity Ratio: -1.69%
  • Current Ratio: 3.43%
  • Quick Ratio: 3.41%
Additional Links:
Companies Related to Immunomedics:

Analyst Ratings

Consensus Ratings for Immunomedics (NASDAQ:IMMU) (?)
Ratings Breakdown: 1 Hold Rating, 1 Buy Rating
Consensus Rating:Buy (Score: 2.50)
Consensus Price Target: $5.00 (52.91% upside)

Analysts' Ratings History for Immunomedics (NASDAQ:IMMU)
Show:
DateFirmActionRatingPrice TargetDetails
6/21/2016Wells Fargo & Co.DowngradeOutperform -> Market PerformView Rating Details
6/6/2016Jefferies GroupReiterated RatingBuy$5.00View Rating Details
7/29/2015Oppenheimer Holdings Inc.Reiterated RatingOutperformView Rating Details
9/30/2014Panmure GordonReiterated RatingBuyView Rating Details
(Data available from 9/25/2014 forward)

Earnings

Earnings History for Immunomedics (NASDAQ:IMMU)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
8/17/2016        
8/17/2016Q416($0.11)($0.17)$1.20 millionViewListenView Earnings Details
5/4/2016Q3($0.13)($0.15)$2.13 millionViewN/AView Earnings Details
2/3/2016Q216($0.14)($0.15)$1.23 millionViewN/AView Earnings Details
11/5/2015Q116($0.14)($0.16)$1.23 millionViewN/AView Earnings Details
8/19/2015Q415($0.13)($0.13)$1.13 million$2.40 millionViewListenView Earnings Details
5/6/2015($0.13)($0.13)ViewN/AView Earnings Details
2/5/2015Q215($0.13)($0.12)$1.38 millionViewN/AView Earnings Details
11/5/2014($0.12)($0.13)ViewN/AView Earnings Details
8/25/2014Q414($0.12)($0.13)$1.20 million$1.20 millionViewN/AView Earnings Details
5/7/2014($0.11)($0.11)ViewN/AView Earnings Details
2/10/2014Q214($0.10)($0.10)$1.20 million$1.20 millionViewN/AView Earnings Details
8/22/2013Q4 2013($0.12)($0.09)$0.81 million$1.40 millionViewN/AView Earnings Details
5/8/2013Q3 2013($0.10)$0.11$0.97 million$1.70 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Immunomedics (NASDAQ:IMMU)
Current Year EPS Consensus Estimate: $-0.47 EPS
Next Year EPS Consensus Estimate: $-0.38 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q2 20161($0.13)($0.13)($0.13)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Immunomedics (NASDAQ:IMMU)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Immunomedics (NASDAQ:IMMU)
Insider Ownership Percentage: 8.80%
Institutional Ownership Percentage: 53.79%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/24/2016Don C StarkDirectorSell9,900$2.97$29,403.00View SEC Filing  
8/23/2016Mary E PaetzoldDirectorSell15,000$2.98$44,700.00View SEC Filing  
6/13/2016Cynthia L GoldenbergCEOSell371,990$3.03$1,127,129.70View SEC Filing  
6/8/2016Cynthia L GoldenbergCEOSell41,441$3.62$150,016.42View SEC Filing  
6/8/2016David M GoldenbergChairmanSell353,010$3.88$1,369,678.80View SEC Filing  
6/7/2016Cynthia L GoldenbergCEOSell4,600$4.01$18,446.00View SEC Filing  
6/7/2016David M GoldenbergChairmanSell12,300$3.98$48,954.00View SEC Filing  
6/6/2016Cynthia L GoldenbergCEOSell63,959$4.09$261,592.31View SEC Filing  
6/6/2016David M GoldenbergChairmanSell110,322$4.09$451,216.98View SEC Filing  
6/15/2015David M GoldenbergChairmanSell210,991$4.08$860,843.28View SEC Filing  
6/12/2015Brian A MarkisonDirectorSell5,564$4.22$23,480.08View SEC Filing  
6/12/2015David M GoldenbergChairmanSell359,653$4.32$1,553,700.96View SEC Filing  
6/9/2015Mary E PaetzoldDirectorSell4,677$4.60$21,514.20View SEC Filing  
6/5/2015Don C StarkDirectorSell5,732$4.14$23,730.48View SEC Filing  
12/11/2014Mary E PaetzoldDirectorSell10,000$4.71$47,100.00View SEC Filing  
12/9/2014Don C StarkDirectorSell5,500$4.51$24,805.00View SEC Filing  
9/13/2013Don StarkDirectorSell10,000$6.08$60,800.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Immunomedics (NASDAQ:IMMU)
DateHeadline
newsmaker.com.au logo2016 H2 Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline Market Outlook Research (NASDAQ:IMMU)
www.newsmaker.com.au - September 23 at 5:18 PM
News IconNew report examines the Global antibody drug conjugate market outlook 2016: adc drugs, adcetris, kadcyla (NASDAQ:IMMU)
www.whatech.com - September 23 at 5:18 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:IMMU)
biz.yahoo.com - September 23 at 5:17 PM
News IconImmunomedics, Inc. (IMMU) Trading Down 18.3% After Insider Selling - DailyQuint (NASDAQ:IMMU)
dailyquint.com - September 22 at 3:39 PM
News IconIntraday Active Biotech Stocks News: OvaScience (NASDAQ:OVAS), Immunomedics (NASDAQ:IMMU) - The Voice Registrar (NASDAQ:IMMU)
voiceregistrar.com - September 22 at 3:39 PM
News IconBiotech Stocks To Put On Your Watch List: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Immunomedics Inc ... - The Voice Registrar (NASDAQ:IMMU)
voiceregistrar.com - September 21 at 9:48 AM
News IconInvestor's Alert: Immunomedics, Inc. (NASDAQ:IMMU), BlackBerry Limited (NASDAQ:BBRY) - Newburgh Press (NASDAQ:IMMU)
newburghpress.com - September 21 at 9:48 AM
News IconTrading the Biotech News: Opko Health, Inc. (NASDAQ:OPK), Immunomedics Inc. (NASDAQ:IMMU) - The Voice Registrar (NASDAQ:IMMU)
voiceregistrar.com - September 21 at 9:48 AM
News IconNew Report Examines The United States Cytotoxic Drug Market 2016 (NASDAQ:IMMU)
www.pharmiweb.com - September 20 at 10:45 AM
News IconQY Research Groups :United States Miacalcin Nasal Spray Market Report 2016 (NASDAQ:IMMU)
www.medgadget.com - September 20 at 10:45 AM
News IconGlobal Radioactive Monoclonal Antibody Sales Market Report 2016 is released (NASDAQ:IMMU)
www.idatainsights.com - September 16 at 5:28 PM
News IconImmunomedics Inc (NASDAQ:IMMU) Is About To Announce A Big Name Partnership (NASDAQ:IMMU)
streetregister.com - September 16 at 5:28 PM
News IconStock Update, a Closer Look at Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 16 at 9:31 AM
News IconImmunomedics Inc (NASDAQ:IMMU) Is About To Announce A Big Name Partnership - Street Register (NASDAQ:IMMU)
streetregister.com - September 16 at 9:31 AM
News IconTop Earnings to Watch for: Immunomedics Inc. (NASDAQ:IMMU) - The Voice Registrar (NASDAQ:IMMU)
voiceregistrar.com - September 16 at 9:31 AM
News IconGlobal Radiation Therapy Sales Market Report 2016 is released (NASDAQ:IMMU)
www.idatainsights.com - September 15 at 5:57 PM
News IconKeen Investors Narrowing Their Focus on Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 15 at 8:48 AM
realistinvestor.com logoImmunomedics, Inc. (NASDAQ:IMMU) Is Expected To Post EPS Of $-0.12 - RealistInvestor.com (NASDAQ:IMMU)
www.realistinvestor.com - September 15 at 8:48 AM
openpr.com logoGlobal Antibody Drug Conjugate Market Outlook 2016: ADC Drugs, Adcetris, Kadcyla (NASDAQ:IMMU)
www.openpr.com - September 14 at 9:50 AM
News IconGlobal cancer immunotherapies Market 2016:Melanoma, Prostate cancer, NSCLC (NASDAQ:IMMU)
www.medgadget.com - September 14 at 9:50 AM
News IconGlobal Lymph Node Dissection Sales Industry Forecast to 2021 with Key Companies Profile, Supply, Demand, Cost Structure, and SWOT Analysis (NASDAQ:IMMU)
empowerednews.net - September 14 at 9:50 AM
News IconPenny Stock Investors Highly Curious in Shares of Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 13 at 10:26 AM
News IconGetting a Closer Look at Shares of Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 12 at 5:30 PM
News IconMaking News: Targeting shares of Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 9 at 5:26 PM
News IconHC Trending Hot Stocks= Immunomedics, Inc. (IMMU), Sanofi SA (ADR) (NYSE:SNY) - share market updates (press release) (NASDAQ:IMMU)
sharemarketupdates.com - September 9 at 10:20 AM
News Icon2 Biotech Stocks News And Price Trends: Immunomedics Inc. (NASDAQ:IMMU), Arrowhead Pharmaceuticals, Inc ... - The Voice Registrar (NASDAQ:IMMU)
voiceregistrar.com - September 9 at 10:20 AM
News IconFocusing the Spotlight on Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 8 at 5:30 PM
News IconHow These Biotech Stocks are Faring? -- Immunomedics, Sequenom, INSYS Therapeutics, and Regulus Therapeutics (NASDAQ:IMMU)
www.kait8.com - September 8 at 9:32 AM
News IconGrowth Analysis of Global Autoimmune Drugs Market 2016-2020 (NASDAQ:IMMU)
reports.pr-inside.com - September 7 at 5:46 PM
News IconOTC Investors Supremely Interested in Shares of Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 6 at 5:35 PM
News Icon2 Biotech Stocks News And Price Trends: Immunomedics Inc ... - The Voice Registrar (NASDAQ:IMMU)
voiceregistrar.com - September 6 at 5:35 PM
capitalcube.com logoETF’s with exposure to Immunomedics, Inc. : September 6, 2016 (NASDAQ:IMMU)
www.capitalcube.com - September 6 at 5:35 PM
News IconGlobal Patanase Market Trend and Forecast to 2021 (NASDAQ:IMMU)
www.medgadget.com - September 3 at 10:10 AM
News IconA Second Look at Shares of Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 2 at 5:34 PM
News IconTaking a Serious Look at Immunomedics Inc. (NASDAQ:IMMU) - Duncan Research (NASDAQ:IMMU)
www.duncanindependent.com - September 1 at 8:35 AM
publicnow.com logoIMMUNOMEDICS TO PRESENT AT UPCOMING INVESTOR CONFERENCES (NASDAQ:IMMU)
www.publicnow.com - August 31 at 10:26 AM
News IconImmunomedics, Inc. (NASDAQ:IMMU) Upgrades/Downgrades Report - Newburg Press (NASDAQ:IMMU)
newburghpress.com - August 30 at 8:49 AM
News IconIntraday Active Biotech Stocks News: Relypsa, Inc. (NASDAQ:RLYP), Immunomedics Inc. (NASDAQ:IMMU) - The Voice Registrar (NASDAQ:IMMU)
voiceregistrar.com - August 29 at 10:09 AM
capitalcube.com logoETF’s with exposure to Immunomedics, Inc. : August 26, 2016 (NASDAQ:IMMU)
www.capitalcube.com - August 26 at 5:28 PM
finance.yahoo.com logoIMMUNOMEDICS INC Financials (NASDAQ:IMMU)
finance.yahoo.com - August 25 at 5:40 PM
capitalcube.com logoImmunomedics, Inc. :IMMU-US: Earnings Analysis: 2016 By the Numbers : August 25, 2016 (NASDAQ:IMMU)
www.capitalcube.com - August 25 at 10:38 AM
kcregister.com logoTraders Are Watching: Immunomedics Inc. (NASDAQ:IMMU), Alibaba Group Holding Ltd (NYSE:BABA), Marchex, Inc ... - KC Register (NASDAQ:IMMU)
www.kcregister.com - August 22 at 10:13 AM
4-traders.com logoIMMUNOMEDICS : ANNOUNCES CONFERENCE CALL AND WEBCAST FOR FOURTH QUARTER AND FISCAL YEAR 2016 FINANCIAL RESULTS (NASDAQ:IMMU)
www.4-traders.com - August 19 at 5:36 PM
investors.com logoImmunomedics hails latest pre-clinical results in cancer study - Proactive Investors USA & Canada (NASDAQ:IMMU)
www.proactiveinvestors.com - August 19 at 8:34 AM
4-traders.com logoIMMUNOMEDICS : Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-K) (NASDAQ:IMMU)
www.4-traders.com - August 18 at 5:38 PM
investors.com logoImmunomedics hails latest pre-clinical results in cancer study (NASDAQ:IMMU)
www.proactiveinvestors.com - August 18 at 5:38 PM
marketwatch.com logo10-K: IMMUNOMEDICS INC (NASDAQ:IMMU)
www.marketwatch.com - August 18 at 5:38 PM
finance.yahoo.com logoEdited Transcript of IMMU earnings conference call or presentation 17-Aug-16 9:00pm GMT (NASDAQ:IMMU)
finance.yahoo.com - August 18 at 5:38 PM
biz.yahoo.com logoIMMUNOMEDICS INC Files SEC form 10-K, Annual Report (NASDAQ:IMMU)
biz.yahoo.com - August 18 at 5:38 PM
News IconEarnings Watch: Immunomedics, Inc. (NASDAQ:IMMU) - Post Registrar (NASDAQ:IMMU)
postregistrar.com - August 18 at 8:38 AM

Social

Immunomedics (NASDAQ:IMMU) Chart for Sunday, September, 25, 2016


Last Updated on 9/25/2016 by MarketBeat.com Staff